Arimidex (anastrozole) - oral aromatase inhibitor - AstraZeneca

Go to navigation
Go to content

Arimidex™ (anastrozole), an oral aromatase inhibitor (AI), is an endocrine (hormonal) therapy for the treatment of hormone-sensitive breast cancer in postmenopausal women. ARIMIDEX was first launched in 1995 for the treatment of advanced disease and the first approvals for early breast cancer treatment followed in 2002.

Did you know?

AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.

Links to country-specific websites can be found using the AstraZeneca websites list.

If you still have a question regarding our drug portfolio you can Contact us.

Not signed in

Page tools

Share price

London: 26.95 GBP
New York: 44.82 USD
Stockholm: 310.10 SEK

At 21-Nov-2009 04:32 GMT

Detailed share price

Introduction to AstraZeneca

Our responsibility

We continue to communicate openly on a range of issues, including:

Did you know

Contact us

Email enquiry form

This website is intended for people seeking information on the AstraZeneca International business. If you are in the US you should visit AstraZeneca US.

We also have national business sites which can be found under our list of AstraZeneca websites.

We also have specific national and international websites designed for patients and healthcare professionals. If you have a question you can contact us.